Detalhe da pesquisa
1.
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
N Engl J Med
; 387(4): 310-320, 2022 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35830649
2.
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
Oncologist
; 27(10): 864-873, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35948003
3.
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Blood
; 135(10): 735-742, 2020 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31945149
4.
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Haematologica
; 107(5): 1086-1094, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162178
5.
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.
Hematol Oncol
; 39(2): 185-195, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462822
6.
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Blood
; 131(11): 1183-1194, 2018 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29229594
7.
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Blood
; 130(25): 2709-2717, 2017 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28974506
8.
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Haematologica
; 109(3): 982-987, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37794803
9.
Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-Risk Classical Hodgkin Lymphoma.
Clin Cancer Res
; 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38810021
10.
Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
J Med Econ
; 25(1): 324-333, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172685
11.
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Blood Adv
; 6(19): 5550-5555, 2022 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35470385
12.
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
Lancet Haematol
; 8(6): e410-e421, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34048680
13.
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.
Leuk Lymphoma
; 61(12): 2931-2938, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32842815
14.
Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
J Med Econ
; 22(2): 117-130, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30375910
15.
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
Clin Cancer Res
; 25(6): 1718-1726, 2019 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30617130
16.
Eating School Lunch Is Associated with Higher Diet Quality among Elementary School Students.
J Acad Nutr Diet
; 116(11): 1817-1824, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27216647
17.
School Breakfast Policy Is Associated with Dietary Intake of Fourth- and Fifth-Grade Students.
J Acad Nutr Diet
; 116(3): 449-457, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26433452
18.
Eat lunch first or play first? Inconsistent associations with fruit and vegetable consumption in elementary school.
J Acad Nutr Diet
; 115(4): 585-92, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25487854